Boxer Capital’s Esperion Therapeutics ESPR Stock Holding History

Boxer Capital’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-500,000	Closed	-$10.6M	–	94
2021 Q2	$10.6M	Hold	500,000	–	–	0.37%	63
2021 Q1	$14M	Hold	500,000	–	–	0.48%	55
2020 Q4	$13M	Sell	500,000 -475,000	-49%	-$14.2M	0.42%	52
2020 Q3	$36.2M	Hold	975,000	–	–	1.25%	18
2020 Q2	$50M	Hold	975,000	–	–	2.2%	11
2020 Q1	$30.7M	Hold	975,000	–	–	2.1%	13
2019 Q4	$58.1M	Hold	975,000	–	–	3.29%	9
2019 Q3	$35.7M	Hold	975,000	–	–	2.59%	13
2019 Q2	$45.4M	Hold	975,000	–	–	3.9%	7
2019 Q1	$39.1M	Sell	975,000 -225,000	-19%	-$10.1M	4.53%	8
2018 Q4	$55.2M	Sell	1,200,000 -175,000	-13%	-$8.43M	6.82%	7
2018 Q3	$61M	Hold	1,375,000	–	–	6.77%	6
2018 Q2	$53.9M	Buy	1,375,000 +475,000	+53%	+$24M	6.1%	7
2018 Q1	$65.1M	Buy	900,000 +100,000	+13%	+$7.34M	6.95%	4
2017 Q4	$52.7M	Buy	800,000 +300,000	+60%	+$16.2M	9.63%	4
2017 Q3	$25.1M	Sell	500,000 -500,000	-50%	-$24.1M	5.71%	6
2017 Q2	$46.3M	Sell	1,000,000 -275,000	-22%	-$10.1M	11.01%	3
2017 Q1	$45M	Buy	+1,275,000	New	+$29.2M	9.84%	4

Other funds holding ESPR

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Boxer Capital's ESPR Position: Q3 2021 in Review

Boxer Capital sold out of Esperion Therapeutics (ESPR) in Q3 2021, closing a stake of 500,000 shares — an estimated $10.6M sold.

Boxer Capital first reported a position in ESPR in Q1 2017 and held it in 18 quarters. The position peaked at $65.1M in Q1 2018. 139 funds tracked by Wall St. Rank hold ESPR as of Q3 2021.

Boxer Capital reported no remaining Esperion Therapeutics position as of Q3 2021 after selling out during the quarter.
Boxer Capital sold 500,000 Esperion Therapeutics shares in Q3 2021, an estimated $10.6M.
Boxer Capital first reported a position in Esperion Therapeutics in Q1 2017 and held it in 18 quarters.
Boxer Capital's Esperion Therapeutics position peaked at $65.1M in Q1 2018.
139 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2021.

Based on Boxer Capital's 13F filing for Q3 2021, filed 15 Nov 2021.